Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05605964 · ClinicalTrials.gov registry record · Phase 3
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
A Phase 3 study of Prostate Cancer, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 387
- Enrollment target
- 20
- Study locations
NCT05605964 is a Phase 3 study of Prostate Cancer that has completed, run by Sumitomo Pharma America. The registered enrollment target is 387 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05605964, a Phase 3 study of Prostate Cancer, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 387 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enrollment in this study was discontinued by the Sponsor on 01 Dec 2023. In an effort to mitigate any treatment interruptions, actively enrolled patients will be allowed to remain on study drug up to a period of 12 months ending Dec 2024 if they choose to remain in the discontinuation phase of the study.
Conditions Studied
Interventions
- DRUG Relugolix
- DRUG Leuprolide Acetate
Study Locations (20)
California
- Genesis Research, LLC Satellite - Downey
- Orange Coast Memorial Medical Center - Fountain Valley
- Genesis Research , LLC - Los Alamitos
- Tower Urology - Los Angeles
- Pacific Cancer Care - Monterey
- Tri Valley Urology Medical Group - Murrieta
- Tri Valley Urology Medical Group Satellite - Murrieta
- San Bernadino Urological Associates Medical Group - San Bernardino
- Genesis Research, LLC - San Diego
- Genesis Research, LLC Satellite - Sherman Oaks
- Tri Valley Urology Medical Group Satellite - Temecula
- Genesis Research, LLC Satellite - Torrance
- Genesis Research, LLC Satellite - Torrance
District of Columbia
- Medstar Washington Hospital Center - Washington D.C.
- Urologic Surgeons of Washington - Washington D.C.
Florida
- Advanced Urology Institute - Daytona Beach
- East Coast Institute for Research, LLC Satellite - Jacksonville
Alabama
- Urology Associates of Mobile - Mobile
Arizona
- Arizona Urology Specialists, PLLC - Tucson
Arkansas
- Arkansas Urology - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2023-01-25 |
| Est. Completion | 2025-01-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05605964
The ClinicalTrials.gov registry entry for NCT05605964 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 387 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (36% lower). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Relugolix is the first listed.
NCT05605964 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, District of Columbia, Florida.
Frequently Asked Questions
What is clinical trial NCT05605964 about?
NCT05605964 is a clinical study titled "Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate". This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enrollment in this study was discontinued by the Sponsor on 01 Dec 2023. In an effort to mitigate any treatment interruptions, actively enrolled patients wil...
What is the current status of trial NCT05605964?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 387 participants. The study started on 2023-01-25. Estimated completion is 2025-01-02.
What conditions does trial NCT05605964 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05605964?
The interventions under investigation include: Relugolix (DRUG), Leuprolide Acetate (DRUG).
Who is sponsoring clinical trial NCT05605964?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05605964 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.